secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEXGEL, INC. (NXGL)
CIK:        0001468929
Form:       8-K
Filed at:   2026-08-21T20:42:03+00:00
Accession:  0001493152-26-039708
Event type: leadership
Sentiment:  neutral
Materiality: 0.75
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NexGel terminates CEO Adam Levy, appoints Brian Kieser interim CEO, launches strategic review
--------------------------------------------------------------------------------

- Adam R. Levy terminated as CEO without cause effective Aug 21, 2026; resigned from board and all officer positions.
- Brian Kieser appointed Interim CEO effective Aug 21, 2026; is CEO of Fountainhead Lifesciences and board member since May 6, 2026.
- Board formed Special Committee for Strategic Review and Value Creation (Kevin Harris, Chair; Steve Glassman) to assess operations.
- Committee authorized to evaluate divestiture, partnerships, restructuring or wind-down of non-core assets; initial framework expected in 30-45 days.
- Levy to provide 90-day transition assistance; Separation Agreement terms not yet finalized, with 8-K amendment to follow.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1468929/000149315226039708/0001493152-26-039708-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1468929/000149315226039708/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-039708

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer